Holen Sie sich die Stockscreener-App
25.11
0.56%
0.14
Handel nachbörslich:
25.11
Janux Therapeutics Inc Aktie (JANX) Neueste Nachrichten
What makes Janux Therapeutics Inc. stock price move sharplyWeekly Risk Report & Smart Investment Allocation Insights - sundaytimes.kr
Buy Rating for Janux Therapeutics Driven by Promising Tumor-Conditional Masking Platform and Strategic Collaborations - TipRanks
Janux Therapeutics Inc. At Critical Juncture — Bounce or BreakdownJuly 2025 Retail & Fast Moving Stock Trade Plans - sundaytimes.kr
Promising Future for Janux Therapeutics: Buy Rating Backed by Strong Clinical Profile and Strategic Trials - TipRanks
Janux Therapeutics Inc. Sees Relief Buying After Extended Drop2025 Institutional Moves & Fast Moving Stock Trade Plans - metal.it
What are JACS’s earnings expectationsConsistent Triple Digit Profits - classian.co.kr
EGFR Non-Small Cell Lung Cancer Clinical Trials, Companies, - openPR.com
EGFR Non-Small Cell Lung Cancer Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Cullinan Oncology, Betta Pharmaceuticals, G1 Therapeutics, Janux - Barchart.com
Promising Pipeline and Financial Stability Support Buy Rating for Janux Therapeutics Inc - TipRanks
Promising Developments and Strategic Expansion at Janux Therapeutics: Analyst Sets $70 Price Target - TipRanks
Janux Therapeutics Earns Buy Rating Amid Promising Pipeline and Strong Financial Position. - AInvest
RSI Crosses Above 30 for Janux Therapeutics Inc. — Reversal in SightTarget Return Focused Trade Insights Shared - metal.it
Buy Rating for Janux Therapeutics Driven by Promising Pipeline and Strong Financial Position - TipRanks
A Quick Look at Today's Ratings for Janux Therapeutics(JANX.US), With a Forecast Between $59 to $100 - 富途牛牛
Janux Therapeutics 2024 Q3 Earnings Widening Losses Amidst Revenue Decline - AInvest
Janux Therapeutics stock hits 52-week low at 22.25 USD - Investing.com
Janux Therapeutics stock hits 52-week low at 22.25 USD By Investing.com - Investing.com Nigeria
Janux (JANX) R&D Soars Revenue Misses - AOL.com
Janux Therapeutics Reports Q2 2025 Financial Results - TipRanks
Janux Therapeutics 2024 Q3 Earnings Deepening Losses Amid Pipeline Progress - AInvest
Janux Therapeutics Stock Maintains Buy Rating: Strong Cash Position and Promising '007 Program Drive Optimism - AInvest
Optimistic Outlook for Janux Therapeutics: Strong Cash Position and Promising ‘007 Program Drive Buy Rating - TipRanks
Optimistic Buy Rating for Janux Therapeutics Inc. Driven by Promising R&D, Strong Cash Position, and Strategic Expansion - TipRanks
Janux Therapeutics reports Q2 EPS (55c), consensus (47c) - TipRanks
Janux Therapeutics Reports Q2 FY25 Financial Results, $996mln Cash, Milestone Payment from Merck. - AInvest
Janux Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights - Business Wire
Janux Therapeutics shares fall 4.94% intraday despite dosing first patient in TRACTr collaboration with Merck. - AInvest
Janux Therapeutics reaches clinical milestone in Merck TRACTr collaboration - TipRanks
Janux Therapeutics Announces Clinical Milestone Achievement in TRACTr Collaboration With Merck - Business Wire
Is Janux Therapeutics Inc. a growth stock or a value stockSuperior return velocity - Jammu Links News
What analysts say about Janux Therapeutics Inc. stockTrack top-performing stocks in real-time - Jammu Links News
What are the latest earnings results for Janux Therapeutics Inc.Build wealth faster with consistent investment plans - Jammu Links News
Should I hold or sell Janux Therapeutics Inc. stock in 2025Free Market Dynamics Reports - Jammu Links News
What drives Janux Therapeutics Inc. stock priceExplosive trading growth - Jammu Links News
Janux Therapeutics Inc. Stock Analysis and ForecastAchieve breakthrough gains with expert advice - Jammu Links News
How does Janux Therapeutics Inc. generate profit in a changing economyMaximize your gains with professional insights - Jammu Links News
Is Janux Therapeutics Inc. stock overvalued or undervaluedMaximize gains with data-driven stock picks - Jammu Links News
What are analysts’ price targets for Janux Therapeutics Inc. in the next 12 monthsUnlock your portfolio’s hidden potential - Jammu Links News
How does Janux Therapeutics Inc. compare to its industry peersAccelerated financial growth - Jammu Links News
Can Janux Therapeutics Inc. Regain Momentum After BreakdownReal Trader Watchlist of Hot Stocks Released - metal.it
Janux: A High-Risk/High-Reward Bet On Oncology And Autoimmune Therapies Backed By $1B In Cash - Seeking Alpha
Optimistic Buy Rating for Janux Therapeutics Driven by Strategic Pipeline and Diversification - TipRanks
Why Janux Therapeutics Inc. stock attracts strong analyst attentionTriple Return Setup With Risk Control Explained - metal.it
Janux Therapeutics Receives Buy Rating from Leerink Partners Analyst Jeffrey La Rosa - AInvest
Why did JANX's operating expenses surge in Q3 2024? - AInvest
Analysts Are Bullish on These Healthcare Stocks: Ionis Pharmaceuticals (IONS), Janux Therapeutics Inc (JANX) - The Globe and Mail
Analysts Praise Ionis Pharmaceuticals and Janux Therapeutics for Bright Healthcare Futures - AInvest
JonesTrading Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $90 - 富途牛牛
H.C. Wainwright Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $70 - 富途牛牛
0.41%
0.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):